Dandelion
Also sold as: Taraxacum officinale · Dandelion leaf · Dandelion root
A traditional bitter herb sold for digestion, water loss and liver support. Human evidence is sparse, and leaf extract and root powder have conflicting diuresis findings.
Longevity
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Longevity: Human longevity benefit is unestablished; this UI classification reflects absence of supporting trials, not a negative lifespan RCT.
REALITY CHECK // The best-known human finding is a small leaf-extract pilot without placebo, contradicted in scope by a root-powder trial with no extra diuresis over water. Neither liver detox nor fat loss nor cancer treatment has demonstrated clinical efficacy; leaf and root cannot be treated as interchangeable.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
01 // STUDIED_DOSE_RANGE
Trial exposure, not an individual prescription
The positive human study used fresh hydroethanolic leaf extract for one day; the null controlled study used commercial root powder over four hours. Exact comparable mg exposures are not supplied in the extracted dossier, so no numeric trial range can be assigned.
02 // TIMING_&_MATRIX
Route and formulation matter
The leaf pilot used fresh hydroethanolic extract. Tea strength, root powder and alcohol tinctures cannot be matched by capsule count or a guessed extraction ratio.
03 // EVALUATION_WINDOW
Match the study window
Human diuresis observations lasted one day or four hours. They do not establish sustained diuresis or long-term liver outcomes.
04 // SAFETY_&_QUALITY_GATE
Clinical review and label check
Avoid unsupervised use with biliary obstruction, gallstones or acute cholecystitis. Review Asteraceae allergy, latex contact reactions, kidney stones, and kidney/heart disease requiring fluid or electrolyte control. Pregnancy/lactation safety is inadequate. Stop for allergy, persistent GI symptoms, dizziness or dehydration.
UPPER LIMIT // No formal comparable EFSA/NIH UL is documented. Sparse human safety data and low acute animal toxicity do not establish a safe chronic dose.
Summary
A small uncontrolled leaf-extract pilot suggested increased urination over one day, while a controlled 2026 root-powder trial found no extra diuresis over water at four hours. Liver, glucose, fat-loss and anticancer narratives are chiefly animal or cell findings, not demonstrated human benefits.
Mechanism
Bitter constituents and inulin in the root underpin digestive hypotheses. Cell/animal studies examine antioxidant, inflammatory, glucose and bile-acid/FXR pathways; these do not establish clinical liver protection or fat loss.
Typical studied dose
The positive human study used fresh hydroethanolic leaf extract for one day; the null controlled study used commercial root powder over four hours. Exact comparable mg exposures are not supplied in the extracted dossier, so no numeric trial range can be assigned.
Upper limit
No formal comparable EFSA/NIH UL is documented. Sparse human safety data and low acute animal toxicity do not establish a safe chronic dose.
Popular stacks with Dandelion
Not enough stack data yet. A combination with Dandelion appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Dandelion leaf / fresh leaf extract Best for: Identifying the leaf preparation used in the uncontrolled diuresis pilot. |
Unstandardized: active content unknown | no comparable trial range | No verified human PK or standardized marker conversion. Usually tolerated; concentrated preparations can cause nausea/headache. |
Studied standard [FORM // REFERENCE] No exact extract mass or herb ratio is indexed. Zero marker and trial range mean unknown, not zero activity. |
| Dandelion root powder / extract Best for: Distinguishing the commonly sold root from leaf evidence. |
Unstandardized: active content unknown | no comparable trial range | Root and extract strengths vary; no verified human conversion. Inulin/FOS may cause bloating and gas. |
Caution [FORM // CAUTION] The up-to-about-40% seasonal inulin content of raw root is not a verified product standardization or diuretic active fraction. Controlled root-powder diuresis study was null. |
| Dandelion hydroethanolic tincture Best for: Form identification only. |
Unstandardized: active content unknown | no comparable trial range | No verified human PK; the cited tincture study is preclinical. Alcohol content matters; GI discomfort possible. |
Caution [FORM // CAUTION] No generic herb-to-extract ratio is known; do not infer a human dose from animal work. |
Common label traps
- TRAP_01 // KILLS 95% OF CANCER CELLS
The viral claim concerns direct extract exposure in laboratory cancer models, not cancer treatment after drinking tea. - TRAP_02 // LIVER DETOX OR FAT BURNER
Liver and metabolic pathways are preclinical. Water loss is not fat loss; meaningful human weight-loss evidence is absent. - TRAP_03 // A NATURAL DIURETIC EQUIVALENT TO A MEDICINE
A small uncontrolled leaf pilot and null root trial cannot justify replacing prescribed diuretics.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- Diuresis: leaf versus root Anecdotal · benefit
The 2009 single-arm fresh-leaf extract pilot suggested increased frequency/volume within about five hours without placebo. The 2026 root-powder controlled trial found no added diuresis versus water over four hours in active young adults. These different organs/preparations are not interchangeable; sustained benefit is unestablished.
PMID 19678785 PMID 42398668 - Liver and digestive support No established evidence
Mouse/chick and other preclinical findings concern liver injury, fatty liver and bile-acid/FXR signaling. No demonstrated human therapeutic benefit; avoid self-treatment with gallstones or obstructed bile ducts.
PMID 23256442 PMID 23603008 PMID 40404059 PMID 41419042 PMID 40732279 - Inflammation and oxidative stress No established evidence
Cell, zebrafish and rodent findings are mechanistic signals, not human clinical outcomes. No human benefit is established.
PMID 17949929 PMID 29187173 PMID 36091818 PMID 22424457 PMID 22480378 - Glucose regulation No established evidence
Enzyme inhibition and insulin/glucose effects are preclinical, including other Taraxacum species; no clinical glucose-lowering benefit is established.
PMID 2743711 PMID 33841825 PMID 41108727 PMID 38024536 - Lipids and body fat No established evidence
HepG2 and animal metabolic/atherosclerosis findings, often in other Taraxacum species, do not prove human fat loss.
PMID 24903219 PMID 33531919 PMID 39408297 PMID 37836404 - Cancer treatment claim No established evidence
Root-extract/taraxasterol effects in laboratory cancer systems do not establish cancer treatment in humans; absence of human efficacy is not a negative cancer RCT.
PMID 27564258 PMID 38766306 - Safety evidence Limited · no benefit
Safety literature remains heavily preclinical. Allergy is a real consideration; absence of a chronic safety trial is not proof of harmlessness.
PMID 41554454 PMID 28169854
Reader questions
Is root the same as root extract or leaf?
No. Plant organ, solvent and concentration change the product; unspecified extracts cannot be equated to the leaf pilot.
Can I use it long term for fluid retention?
Chronic efficacy and safety are unestablished. Fluid retention with heart/kidney disease or medication use needs clinical assessment rather than replacing diuretics.
Does it reduce body fat?
No clinical fat-loss effect is established; short-term changes in water weight do not demonstrate fat loss.
Why can it cause bloating?
Root inulin/FOS may ferment and add to other prebiotic fiber. Persistent pain, vomiting or dehydration merits review.
How strong should my tea be?
The dossier cannot supply a reproducible effective tea dose. Stronger preparation increases uncertainty and can worsen nausea or headache.
Stack interactions
- Caution Lithium [CAUTION // REVIEW_CONTEXT]
Potential fluid/electrolyte changes could alter lithium clearance; direct dandelion interaction trials are absent. Prescriber review and lithium monitoring are needed. - Caution Glucose-lowering medicines [CAUTION // REVIEW_CONTEXT]
Hypoglycemic mechanisms are animal/in-vitro evidence; an additive clinical effect is theoretical, not proven.
PMID 2743711 PMID 33841825 - Caution Warfarin / CYP3A4 substrates [CAUTION // REVIEW_CONTEXT]
Leaf vitamin K and herbal-tea CYP3A4 inhibition in vitro create hypotheses, not quantified human interactions.
PMID 24824478 - Caution Other diuretics, caffeine and prebiotic fiber [CAUTION // REVIEW_CONTEXT]
Potential additional fluid/electrolyte changes and additive inulin/FOS bloating warrant caution; no validated beneficial synergy is established.
Red flags: interactions and who should avoid it
Interactions
Lithium concentrations may change if fluid/electrolyte balance changes; this is an extrapolated caution, not a demonstrated dandelion interaction. Glucose-lowering drug effects are theoretical from preclinical data. Leaf vitamin K and in-vitro CYP3A4 inhibition warrant review with anticoagulants; no clinical warfarin interaction is established. Mineral-related antibiotic binding is only theoretical.
Avoid or ask a doctor first if
Avoid unsupervised use with biliary obstruction, gallstones or acute cholecystitis. Review Asteraceae allergy, latex contact reactions, kidney stones, and kidney/heart disease requiring fluid or electrolyte control. Pregnancy/lactation safety is inadequate. Stop for allergy, persistent GI symptoms, dizziness or dehydration.
Sources (PubMed, 26)
- The diuretic effect in human subjects of an extract of Taraxacum officinale folium over a single day.
PMID 19678785 · 2009 · Human pilot studyThe 2009 single-arm fresh-leaf extract pilot suggested increased frequency/volume within about five hours without placebo. The 2026 root-powder controlled trial found no added diuresis versus water over four hours in active young adults. These different organs/preparations are not interchangeable; sustained benefit is unestablished. No verified human PK or standardized marker conversion. No exact extract mass or herb ratio is indexed. Zero marker and trial range mean unknown, not zero activity.
- Co-Ingestion of a Commercially Available Dandelion Root Powder Elicited No Additional Diuretic Effect Over 4 Hr Compared to Ingestion of Water Alone in Physically Active Young Adults.
PMID 42398668 · 2026 · Randomized controlled trialThe 2009 single-arm fresh-leaf extract pilot suggested increased frequency/volume within about five hours without placebo. The 2026 root-powder controlled trial found no added diuresis versus water over four hours in active young adults. These different organs/preparations are not interchangeable; sustained benefit is unestablished. Root and extract strengths vary; no verified human conversion. The up-to-about-40% seasonal inulin content of raw root is not a verified product standardization or diuretic active fraction. Controlled root-powder diuresis study was null.
- Dandelion leaf extract protects against liver injury induced by methionine- and choline-deficient diet in mice.
PMID 23256442 · 2013 · Preclinical animal studyMouse/chick and other preclinical findings concern liver injury, fatty liver and bile-acid/FXR signaling. No demonstrated human therapeutic benefit; avoid self-treatment with gallstones or obstructed bile ducts.
- Taraxacum official (dandelion) leaf extract alleviates high-fat diet-induced nonalcoholic fatty liver.
PMID 23603008 · 2013 · Preclinical animal studyMouse/chick and other preclinical findings concern liver injury, fatty liver and bile-acid/FXR signaling. No demonstrated human therapeutic benefit; avoid self-treatment with gallstones or obstructed bile ducts.
- Hepatoprotective effects of dandelion against AFB1-induced liver injury are associated with activation of bile acid-FXR signaling in chicks.
PMID 40404059 · 2025 · Preclinical animal studyMouse/chick and other preclinical findings concern liver injury, fatty liver and bile-acid/FXR signaling. No demonstrated human therapeutic benefit; avoid self-treatment with gallstones or obstructed bile ducts.
- Taraxasterol from dandelion improves glycolipid metabolism dysfunction in diet-induced metabolic dysfunction-associated steatotic liver disease by modulating hepatic FXR.
PMID 41419042 · 2026 · Preclinical animal studyMouse/chick and other preclinical findings concern liver injury, fatty liver and bile-acid/FXR signaling. No demonstrated human therapeutic benefit; avoid self-treatment with gallstones or obstructed bile ducts.
- The Role of Dandelion (Taraxacum officinale) in Liver Health and Hepatoprotective Properties.
PMID 40732279 · 2025 · Narrative reviewMouse/chick and other preclinical findings concern liver injury, fatty liver and bile-acid/FXR signaling. No demonstrated human therapeutic benefit; avoid self-treatment with gallstones or obstructed bile ducts.
- Anti-inflammatory activity of Taraxacum officinale.
PMID 17949929 · 2008 · Preclinical animal studyCell, zebrafish and rodent findings are mechanistic signals, not human clinical outcomes. No human benefit is established.
- Anti-inflammatory evaluation of the methanolic extract of Taraxacum officinale in LPS-stimulated human umbilical vein endothelial cells.
PMID 29187173 · 2017 · In-vitro studyCell, zebrafish and rodent findings are mechanistic signals, not human clinical outcomes. No human benefit is established.
- Anti-Inflammatory Effects and Mechanisms of Dandelion in RAW264.7 Macrophages and Zebrafish Larvae.
PMID 36091818 · 2022 · Preclinical animal studyCell, zebrafish and rodent findings are mechanistic signals, not human clinical outcomes. No human benefit is established.
- Antioxidant properties of Taraxacum officinale leaf extract are involved in the protective effect against hepatoxicity induced by acetaminophen in mice.
PMID 22424457 · 2012 · Preclinical animal studyCell, zebrafish and rodent findings are mechanistic signals, not human clinical outcomes. No human benefit is established.
- Antioxidant properties of Taraxacum officinale fruit extract are involved in the protective effect against cellular death induced by sodium nitroprusside in brain of rats.
PMID 22480378 · 2012 · Preclinical animal studyCell, zebrafish and rodent findings are mechanistic signals, not human clinical outcomes. No human benefit is established.
- Glycaemic effects of traditional European plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice.
PMID 2743711 · 1989 · Preclinical animal studyEnzyme inhibition and insulin/glucose effects are preclinical, including other Taraxacum species; no clinical glucose-lowering benefit is established. Hypoglycemic mechanisms are animal/in-vitro evidence; an additive clinical effect is theoretical, not proven.
- Hypoglycemic effect of Taraxacum officinale root extract and its synergism with Radix Astragali extract.
PMID 33841825 · 2021 · In-vitro studyEnzyme inhibition and insulin/glucose effects are preclinical, including other Taraxacum species; no clinical glucose-lowering benefit is established. Hypoglycemic mechanisms are animal/in-vitro evidence; an additive clinical effect is theoretical, not proven.
- Exploring the Antidiabetic Mechanisms of Taraxacum farinosum and Taraxacum mirabile Extracts: Enzyme Inhibition, Insulin Secretion, and LC-HRMS-Based Phytochemical Analysis.
PMID 41108727 · 2025 · In-vitro studyEnzyme inhibition and insulin/glucose effects are preclinical, including other Taraxacum species; no clinical glucose-lowering benefit is established.
- Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV.
PMID 38024536 · 2023 · Narrative reviewEnzyme inhibition and insulin/glucose effects are preclinical, including other Taraxacum species; no clinical glucose-lowering benefit is established.
- Hypolipidemic activity of Taraxacum mongolicum associated with the activation of AMP-activated protein kinase in human HepG2 cells.
PMID 24903219 · 2014 · Preclinical animal studyHepG2 and animal metabolic/atherosclerosis findings, often in other Taraxacum species, do not prove human fat loss.
- Beneficial Effect of Taraxacum coreanum Nakai via the Activation of LKB1-AMPK Signaling Pathway on Obesity.
PMID 33531919 · 2021 · Preclinical animal studyHepG2 and animal metabolic/atherosclerosis findings, often in other Taraxacum species, do not prove human fat loss.
- Taraxacum Mongolicum Polysaccharides Reverses Mice Obesity via Activation of AKT/mTOR Pathway.
PMID 39408297 · 2024 · Preclinical animal studyHepG2 and animal metabolic/atherosclerosis findings, often in other Taraxacum species, do not prove human fat loss.
- Dandelion Polysaccharides Ameliorate High-Fat-Diet-Induced Atherosclerosis in Mice through Antioxidant and Anti-Inflammatory Capabilities.
PMID 37836404 · 2023 · Preclinical animal studyHepG2 and animal metabolic/atherosclerosis findings, often in other Taraxacum species, do not prove human fat loss.
- Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways.
PMID 27564258 · 2016 · Preclinical animal studyRoot-extract/taraxasterol effects in laboratory cancer systems do not establish cancer treatment in humans; absence of human efficacy is not a negative cancer RCT.
- Dandelion root extracts and taraxasterol inhibit LPS‑induced colorectal cancer cell viability by blocking TLR4‑NFκB‑driven ACE2 and TMPRSS2 pathways.
PMID 38766306 · 2024 · In-vitro studyRoot-extract/taraxasterol effects in laboratory cancer systems do not establish cancer treatment in humans; absence of human efficacy is not a negative cancer RCT.
- Unveiling the genus Taraxacum: From folk medicine to chemodiversity-driven pharmacological and toxicological outcomes-A systematic review.
PMID 41554454 · 2026 · Systematic review and meta-analysisSafety literature remains heavily preclinical. Allergy is a real consideration; absence of a chronic safety trial is not proof of harmlessness.
- Dandelion: An Important Allergen in Atopic Children.
PMID 28169854 · 2017 · Study design not fully indexed in dossierSafety literature remains heavily preclinical. Allergy is a real consideration; absence of a chronic safety trial is not proof of harmlessness.
- New Approaches on the Anti-Inflammatory and Cardioprotective Properties of Taraxacum officinale Tincture.
PMID 36986458 · 2023 · Preclinical animal studyNo verified human PK; the cited tincture study is preclinical. No generic herb-to-extract ratio is known; do not infer a human dose from animal work.
- Herbal tea extracts inhibit Cytochrome P450 3A4 in vitro.
PMID 24824478 · 2014 · In-vitro studyLeaf vitamin K and herbal-tea CYP3A4 inhibition in vitro create hypotheses, not quantified human interactions.
Community comments
No approved comments yet. Comments are held for moderation.